	FOR OFFICE USE ONL	Y	
Protocol No:	Approval Date:	Expiration Date:	

APPLICATION FOR RESEARCH OR TEACHING PROJECT INVOLVING RECOMBINANT DNA OR BIOLOGICALLY HAZARDOUS MATERIALS

SANTA CLARA UNIVERSITY BIOSAFETY COMMITTEE						
It is the instructor's or investigator's responsibility to provide complete information about teaching and research procedures involving recombinant DNA (rDNA) and/or biologically hazardous materials. The Santa Clara University Biosafety Committee (BSC) reviews all requests to conduct teaching and/or research activities involving rDNA and biologically hazardous materials. Because the persons reviewing your application may be entirely unfamiliar with the field of study involved, please present the request in non-technical terms understandable to the BSC. Please electronically submit a copy of your complete application and any other material or background information that will assist the Biosafety Committee in its review. Full links to reference materials can be found on page 6 of application.						
	New Application	Annual Renewal:				
Date of Req	uest: Anticij	pated Project End Date:				
Principal Investigator/ Instructor	Department (& course	number, if relevant)	Phone Number: E-mail:			
Other Investigators and/or staff (list all)	Address:		Phone Number(s): E-mail(s):			
Project Title:						
Additional Comments:						
		Check the appropr	iate box			
Does the proposed teaching or research activity involve recombinant DNA? (if you answered yes, complete sections I& III) Reference: Experiments Covered by NIH						
Does the proposed teaching or research activity involve:						
a) Human Embryonic Stem Cell / Derivative?						
b) CDC-listed Biologically Hazardous Agents?						
c) Human blood or other bodily fluids?						
Reference: Biosafety in Microbiological and Biomedic Name of Biohazardous material(s),	cal Laboratories (BMBL)	, 6th edition				
including any applicable cell lines:						
** if you answered no to all the above questions, no	further action is require	d				
I am familiar with and agree to abide by the current NIH guidelines for research involving Recombinant DNA and CDC/NIH Biosafety in the Microbiological, Biomedical Laboratories manual involving Biologically Hazardous Agents and Santa Clara University Biosafety Policy and Procedures. The information in the attached application is accurate and complete.						
Signature, Principal Investigator						
Date						

	ection I: Studies Involving	_	rDNA)					
	heck all of the following the		_		nant DN	A. If you answer YES to any of the		
	Reference: Experiments Cover For Risk Groups, reference		ican Biolog	gical Safe	ety Assoc	iation Risk Group Database		
*/	NIH/Office of Biotechnology	Activities (OBA) and Bios	safety Comi	nittee ap	provals a	are required for the following:		
a.	Experiments involving the	cloning of toxin molecules (Section III-B-1)	with LD50	of less t Yes	han 1 mg	y/ kg body weight No		
**	Biosafety Committee approve	al is required prior to initi	ation of exp	periment	ts that inc	clude the following:		
a.	Experiments using Risk G	roup 2, 3, 4, or Restricted A (Section III-D-1)	Agents as he	ost-vecto Yes	or systems	s No		
b.	_	, 4, or Restricted Agents is	4, or Restricted Agents is cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector					
	systems	(Section III-D-2)		Yes		No		
c. Experiments involving the use of infectious DNA or RNA viruses or defective DNA or RNA viruses in the presence of helper virus in								
tissue culture systems		(Section III-D-3)		Yes		No		
d. Experiments involving whole animals in which the animal's genome has been altered by stable introduction of recombinant DNA, or DNA derived from, into the germ-line (transgenic animals) and experiments involving viable recombinant DNA-modified microorganisms tested on whole animals.								
		(Section III-D-4)		Yes		No		
		If yes, what is the anir	nal species?	,				
						h plants for other experimental purposes (e.g., sms or insects containing recombinant DNA		
		(Section III-D-5)		Yes		No		
f.	Experiments producing more	than 10 Liters of culture of (Section III-D-6)	f organisms	containi Yes	ng Recor	nbinant DNA of Risk Group 1, 2 or 3. No		
g.	Experiments involving influe	nza viruses						
		(Section III-D-7)		Yes		No		

**(continued) Biosafety Comm	ittee approval is required p	prior to ini	itiation oj	^c experim	nents that include the following:
h. Experiments involving the for eukaryotic virus.	rmation of recombinant DN	NA molecu	les contai	ning no	more than two-thirds of the genome of any
	(Section III-E-1)		Yes		No
i. Experiments involving recombinant DNA-modified whole plants, and/or experiments involving recombinant DNA-modified organisms associated with whole plants					
organisms associated with whole	(Section III-E-2)		Yes		No
j. Experiments involving the generation of rodents in which the animal's genome has been altered by stable introduction of recombinant DNA, or DNA derived from into the germ-line (transgenic rodents). Only experiments that require BL1 containment are covered under					
this section	(Section III-E-3)		Yes		No
	<u>Com</u>	plete Secti	ion III		

Section II: Studies Involving Biologically Hazardous Materials					
Referen	nce: Biosafety in Microbiological and Biomedical Laboratories (l	BMBL), 6th editi	ion		
Check all of the following that are applicable to your studies involving biologically hazardous materials. If you answer YES to any of the following conditions, Biosafety Committee approval will be required: *For reference see CDC/NIH guidelines: Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th edition					
a.	Viruses	Yes	No		
b.	Toxins (bacterial, fungal, plant)	Yes	□No		
c.	Other infectious agents, such as prions	Yes	No		
d.	Infected animals & animal tissues	Yes	No		
e.	Human tissue, including scrapings, secretions, body fluids, bones or teeth	☐ Yes	□ No		
f.	A primary cell culture derived from human tissue	□Yes	No		
	(For stem cell line provide source/origin/ name of cell line under sec	ction III)			
g.	Human blood or blood by-products	Yes	□ No		
	<u>Complete Section III</u>				

Section III			
DESCRIPT	ION OF THE EXPERIM	<u>IENT</u>	
1. Provide a	short summary of the proje	ect:	
2. Technical if cells are in		Explain the goal(s) and r	nethods to be used. Description must include any cell lines
3. Location(s) of experiments, containing	nent equipment (i.e. bio l	nood) and storage of biologically active agents:
0	Experiments to be conducted Physical containment equipolation of agents to be stopped to the sto	ment to be used: Biosaf	ety Level (BSL)
	Location of autoclave for y		
4. Describe j will be used		en handling materials. Cl	neck applicable personal protective equipment (PPE) that
	☐ Mask☐Shoe covers☐Safety Glasses	☐ Gloves ☐ Head cover ☐ Respirator	☐ Lab coat ☐ Disposable Gown ☐ Other

5. Describe risk of infection, clinical symptoms, and any recommended medical surveillance and preventive laboratory practices to be used:
6. How do you plan to inactivate the toxin(s) prior to disposal?
6. How do you plan to mactivate the toxin(s) prior to disposar?
7. How do you plan to dispose your biological wastes:
Waste disposal method: Autoclave Biohazardous waste/red bag(incineration)
other, please describe:
8. Indicate training status of all personnel involved in the project:
Completed Bloodborne Pathogens (BBP) training Yes No
**Note: training is required annually; contact EHS to schedule training
Note: training is required annually, contact Errs to senedule training
9. Do you have an emergency spill response plan in place?
A spill kit appropriate for the materials used in the lab must be available and easily accessible. All lab personnel must know how to use it.
Supplemental information:

All Reference Materials-

Experiments Covered by NIH: https://osp.od.nih.gov/wp-content/uploads/2019 NIH Guidelines.htm# Toc3457034

NIH Appendix B: https://osp.od.nih.gov/wp-content/uploads/2019 NIH Guidelines.htm# Toc3457093

Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th edition: http://www.cdc.gov/biosafety/publications/bmbl5/index.htm

American Biological Safety Association Risk Group Database: https://my.absa.org/Riskgroups